Compass Therapeutics
Most recent annual filing: 2026-03-05
- Tovecimig FDA decision3Q 2026Tovecimig FDA decision, 3Q 2026, thesis-defining
- Tovecimig Ph2 start2H 2026Tovecimig Ph2 start, 2H 2026, routine
- Tovecimig BLA filing4Q 2026Tovecimig BLA filing, 4Q 2026, material
- CTX-8371 Ph1 readout4Q 2026CTX-8371 Ph1 readout, 4Q 2026, notable
- CTX-10726 Ph1 readout4Q 2026CTX-10726 Ph1 readout, 4Q 2026, notable
- Tovecimig readoutOct 24, 2026Tovecimig readout, Oct 24, 2026, notable
- Tovecimig FDA approval2H 2027Tovecimig FDA approval, 2H 2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (15 active programs)
CTX-471
- Melanoma
- Small Cell Lung Cancer
- Mesothelioma
- Undisclosed indication
CTX-8371
CTX-10726
- Undisclosed indication
- Renal Cell Carcinoma
- Gastroesophageal Cancer
- Hepatocellular Carcinoma
- Endometrial Cancer
Technology platforms
StitchMabs
Bispecific antibody discovery platform using combinatorial screening of antigen-binding domain pairs across innate and adaptive immune targets; used to identify novel bispecific antibodies for oncology applications
Biotech Distilled coverage (1)
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.